Cargando…
A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease
PURPOSE: The aim of this study was to compare the efficacy of two lipid-based lubricant eye drops in patients with lipid-deficient dry eye. METHODS: This Phase IV, multicenter, prospective, double-masked study enrolled adults (aged ≥18 years) who had a tear film breakup time (TFBUT) of ≤15 seconds(s...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308126/ https://www.ncbi.nlm.nih.gov/pubmed/32606581 http://dx.doi.org/10.2147/OPTH.S256351 |
_version_ | 1783548935767326720 |
---|---|
author | Jerkins, Gary Greiner, Jack V Tong, Louis Tan, Jacqueline Tauber, Joseph Mearza, Ali Srinivasan, Sruthi |
author_facet | Jerkins, Gary Greiner, Jack V Tong, Louis Tan, Jacqueline Tauber, Joseph Mearza, Ali Srinivasan, Sruthi |
author_sort | Jerkins, Gary |
collection | PubMed |
description | PURPOSE: The aim of this study was to compare the efficacy of two lipid-based lubricant eye drops in patients with lipid-deficient dry eye. METHODS: This Phase IV, multicenter, prospective, double-masked study enrolled adults (aged ≥18 years) who had a tear film breakup time (TFBUT) of ≤15 seconds(s), and unanesthetized Schirmer I test of ≥3 mm to ≤12 mm in at least one eye, at both screening and baseline visits. Eligible patients (n=231) were randomized (1:1) and received either Systane(®) Balance (SYSB; n=117) or Refresh(®) Optive Advanced (RFO-Ad, n=114), four-times a day, for 35 days. The primary endpoint was non-inferiority for change from baseline in TFBUT at Day 35 (non-inferiority was established if the lower limit of the 95% confidence interval (CI) for the difference between the treatment groups was > –1.0 s); secondary endpoints (test of superiority) were change in TFBUT and global ocular discomfort visual analog scale (VAS) score at Day 35. Other endpoints included the impact of dry eye on everyday life (IDEEL) treatment satisfaction scores (inconvenience and effectiveness) and safety. RESULTS: At Day 35, the mean change from baseline in TFBUT was 0.998 s in the SYSB and 0.868 s in the RFO-Ad groups with a treatment difference: 0.130 s; (95% CI −0.34, 0.60; P<0.0001) demonstrating non-inferiority of SYSB to RFO-Ad. The global ocular discomfort VAS scores improved in both groups, with a mean change from baseline of –9.7 and –8.8 in SYSB and RFO-Ad groups (treatment difference –0.8; P=0.62), respectively. No meaningful difference was observed in IDEEL treatment effectiveness and treatment inconvenience scores between SYSB vs RFO-Ad (P>0.05 for treatment difference). Both treatments were well tolerated. CONCLUSION: SYSB lubricant eye drops were non-inferior to RFO-Ad for improvement in TFBUT in patients with lipid-deficient dry eye. Both lubricant eye drops improved TFBUT and ocular discomfort scores in patients with lipid-deficient dry eye. |
format | Online Article Text |
id | pubmed-7308126 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-73081262020-06-29 A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease Jerkins, Gary Greiner, Jack V Tong, Louis Tan, Jacqueline Tauber, Joseph Mearza, Ali Srinivasan, Sruthi Clin Ophthalmol Original Research PURPOSE: The aim of this study was to compare the efficacy of two lipid-based lubricant eye drops in patients with lipid-deficient dry eye. METHODS: This Phase IV, multicenter, prospective, double-masked study enrolled adults (aged ≥18 years) who had a tear film breakup time (TFBUT) of ≤15 seconds(s), and unanesthetized Schirmer I test of ≥3 mm to ≤12 mm in at least one eye, at both screening and baseline visits. Eligible patients (n=231) were randomized (1:1) and received either Systane(®) Balance (SYSB; n=117) or Refresh(®) Optive Advanced (RFO-Ad, n=114), four-times a day, for 35 days. The primary endpoint was non-inferiority for change from baseline in TFBUT at Day 35 (non-inferiority was established if the lower limit of the 95% confidence interval (CI) for the difference between the treatment groups was > –1.0 s); secondary endpoints (test of superiority) were change in TFBUT and global ocular discomfort visual analog scale (VAS) score at Day 35. Other endpoints included the impact of dry eye on everyday life (IDEEL) treatment satisfaction scores (inconvenience and effectiveness) and safety. RESULTS: At Day 35, the mean change from baseline in TFBUT was 0.998 s in the SYSB and 0.868 s in the RFO-Ad groups with a treatment difference: 0.130 s; (95% CI −0.34, 0.60; P<0.0001) demonstrating non-inferiority of SYSB to RFO-Ad. The global ocular discomfort VAS scores improved in both groups, with a mean change from baseline of –9.7 and –8.8 in SYSB and RFO-Ad groups (treatment difference –0.8; P=0.62), respectively. No meaningful difference was observed in IDEEL treatment effectiveness and treatment inconvenience scores between SYSB vs RFO-Ad (P>0.05 for treatment difference). Both treatments were well tolerated. CONCLUSION: SYSB lubricant eye drops were non-inferior to RFO-Ad for improvement in TFBUT in patients with lipid-deficient dry eye. Both lubricant eye drops improved TFBUT and ocular discomfort scores in patients with lipid-deficient dry eye. Dove 2020-06-18 /pmc/articles/PMC7308126/ /pubmed/32606581 http://dx.doi.org/10.2147/OPTH.S256351 Text en © 2020 Jerkins et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Jerkins, Gary Greiner, Jack V Tong, Louis Tan, Jacqueline Tauber, Joseph Mearza, Ali Srinivasan, Sruthi A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease |
title | A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease |
title_full | A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease |
title_fullStr | A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease |
title_full_unstemmed | A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease |
title_short | A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease |
title_sort | comparison of efficacy and safety of two lipid-based lubricant eye drops for the management of evaporative dry eye disease |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308126/ https://www.ncbi.nlm.nih.gov/pubmed/32606581 http://dx.doi.org/10.2147/OPTH.S256351 |
work_keys_str_mv | AT jerkinsgary acomparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease AT greinerjackv acomparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease AT tonglouis acomparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease AT tanjacqueline acomparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease AT tauberjoseph acomparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease AT mearzaali acomparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease AT srinivasansruthi acomparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease AT jerkinsgary comparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease AT greinerjackv comparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease AT tonglouis comparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease AT tanjacqueline comparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease AT tauberjoseph comparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease AT mearzaali comparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease AT srinivasansruthi comparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease |